trial

A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

NCTId NCT07061288
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Recruiting
Enrollment 116 (estimated)
Sponsored by Bristol-Myers
Primary completion 2027-06-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Recruiting
Enrollment
116 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
None
Start
2025-09-03
Primary completion
2027-06-21
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Bristol-MyersLead Sponsor

Sites

8 total
Los Alamitos, United StatesHollywood, United StatesMiami Lakes, United StatesAtlanta, United StatesDecatur, United StatesChicago, United StatesMarlton, United StatesAustin, United States

Facts & assertions

4 sourced
Enrollment
116
Phase
PHASE1
Primary Completion Date
2027-06-21
Status
RECRUITING
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Bristol-Myers
company
indication
Schizophrenia
indication
Schizophrenia
indication